Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression
Magdalena Krupa, Marta Cañamero, Carmen Gómez, et al.
Vaccine (2010) Vol. 29, Iss. 7, pp. 1504-1513
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

The Evolution of Poxvirus Vaccines
Lucas Sánchez-Sampedro, Beatriz Perdiguero, Ernesto Mejías‐Pérez, et al.
Viruses (2015) Vol. 7, Iss. 4, pp. 1726-1803
Open Access | Times Cited: 197
DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen
Grace Cole, Ahlam Ali, Emma McErlean, et al.
Acta Biomaterialia (2019) Vol. 96, pp. 480-490
Open Access | Times Cited: 87
CAR-T cell therapy: a potential new strategy against prostate cancer
Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 80
MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
Carmen Gómez, José Luis Nájera, Magdalena Krupa, et al.
Current Gene Therapy (2011) Vol. 11, Iss. 3, pp. 189-217
Closed Access | Times Cited: 111
STEAP1 is overexpressed in cancers: A promising therapeutic target
Jérôme Moreaux, Alboukadel Kassambara, Dirk Hose, et al.
Biochemical and Biophysical Research Communications (2012) Vol. 429, Iss. 3-4, pp. 148-155
Open Access | Times Cited: 84
Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice
Marc Mueller, Wilfried Reichardt, Julia Koerner, et al.
Journal of Controlled Release (2012) Vol. 162, Iss. 1, pp. 159-166
Open Access | Times Cited: 68
DNA vaccines for prostate cancer
Christopher D. Zahm, Viswa T. Colluru, Douglas G. McNeel
Pharmacology & Therapeutics (2017) Vol. 174, pp. 27-42
Open Access | Times Cited: 53
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
Federica Cappuccini, Stephen M. Stribbling, Emily Pollock, et al.
Cancer Immunology Immunotherapy (2016) Vol. 65, Iss. 6, pp. 701-713
Open Access | Times Cited: 49
Expression and Immunotherapeutic Targeting of the SSX Family of Cancer–Testis Antigens in Prostate Cancer
Heath A. Smith, Robert J. Cronk, Joshua M. Lang, et al.
Cancer Research (2011) Vol. 71, Iss. 21, pp. 6785-6795
Open Access | Times Cited: 56
Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
Andrea Kießling, Rebekka Wehner, Susanne Füssel, et al.
Cancers (2012) Vol. 4, Iss. 1, pp. 193-217
Open Access | Times Cited: 51
Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
Sanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
PLoS ONE (2013) Vol. 8, Iss. 2, pp. e55831-e55831
Open Access | Times Cited: 47
The Role of STEAP1 in Prostate Cancer: Implications for Diagnosis and Therapeutic Strategies
Lingling Zhang, Xinyi Ren, Ran An, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 794-794
Open Access
Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1
Érica Araújo Mendes, Flávio Guimarães da Fonseca, Bárbara M. Casério, et al.
PLoS ONE (2013) Vol. 8, Iss. 5, pp. e63201-e63201
Open Access | Times Cited: 30
Prostate cancer vaccines in clinical trials
David M. Lubaroff
Expert Review of Vaccines (2012) Vol. 11, Iss. 7, pp. 857-868
Closed Access | Times Cited: 28
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Federica Cappuccini, Emily Pollock, Stephen M. Stribbling, et al.
Oncotarget (2017) Vol. 8, Iss. 29, pp. 47474-47489
Open Access | Times Cited: 28
Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?
Naomi L. Dunning, Stéphanie A. Laversin, Amanda K. Miles, et al.
Cancer Immunology Immunotherapy (2011) Vol. 60, Iss. 8, pp. 1181-1193
Open Access | Times Cited: 26
Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
Magali Matsumiya, Elena Stylianou, Kristin Griffiths, et al.
PLoS ONE (2013) Vol. 8, Iss. 7, pp. e67922-e67922
Open Access | Times Cited: 26
Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications
Xueling Yang, Zhixing Guo, Ya Liu, et al.
Expert Review of Anticancer Therapy (2013) Vol. 14, Iss. 1, pp. 31-37
Closed Access | Times Cited: 25
DNA vaccination for prostate cancer: key concepts and considerations
Grace Cole, Joanne McCaffrey, Ahlam Ali, et al.
Cancer Nanotechnology (2015) Vol. 6, Iss. 1
Open Access | Times Cited: 23
Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy
Nataliya Prokhnevska, Dana A. Emerson, Haydn Kissick, et al.
Advances in experimental medicine and biology (2019), pp. 121-147
Closed Access | Times Cited: 21
An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms
José M. Arencibia, Wolfgang Fröhner, Magdalena Krupa, et al.
ACS Chemical Biology (2017) Vol. 12, Iss. 2, pp. 564-573
Closed Access | Times Cited: 19
Oral delivery of particulate prostate cancer vaccine:In vitroandin vivoevaluation
Archana Akalkotkar, Suprita A. Tawde, Lipika Chablani, et al.
Journal of drug targeting (2012) Vol. 20, Iss. 4, pp. 338-346
Closed Access | Times Cited: 19
Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 186-193
Xuan Chen, Rui Wang, Anji Chen, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 111, pp. 1124-1131
Open Access | Times Cited: 16
Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model
Brian W. Simons, Fabiana Cannella, D. Rowley, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 4, pp. 641-651
Closed Access | Times Cited: 14
Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
Dimple Chakravarty, Li Huang, Matthew Kahn, et al.
Urologic Clinics of North America (2020) Vol. 47, Iss. 4, pp. 487-510
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top